Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Contradictory Results Are Found in Two Pembrolizumab Trials for Head and Neck Cancer.

2.

Fitness levels for the heart and lungs are linked to a lower mortality from cancer in men.

3.

"Unusual" Cancers Following Pandemic; Triumph in TNBC; Clinical Trial Interrupted by Shortage.

4.

Multiple Myeloma Patients Have Unequal Access to Treatment

5.

Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot